CommercialCoverageMedium impact
Viscosupplementation (CPB 0179, reviewed 2026-09-02)
Aetna·Orthopedics, Rheumatology, PM&R (Physical Medicine & Rehab) +2 more·Medical Policy
We identified it
Oct 6, 2026
Summary
This is a historical medical policy document (CPB 0179) for viscosupplementation (hyaluronate injections) for knee osteoarthritis, newly discovered on 2026-10-06 but last reviewed 2026-09-02. The policy establishes medical necessity criteria for initial approval and continuation of therapy, specifies covered/non-covered CPT codes, and identifies experimental indications. No effective date change is stated in the source; billing teams should verify current applicability with Aetna directly.
Action Required
Billing team should review this historical policy to confirm current applicability with Aetna, as the source states this is a review dated 2026-09-02 with no stated effective date change. Verify: (1) Precertification requirements for viscosupplementation products by contacting (866) 752-7021 or faxing (888) 267-3277 before claim submission; (2) That initial approval criteria are documented in member records (radiographic evidence of knee OA, inadequate response to non-pharmacologic treatment, analgesics for ≥3 months, intraarticular steroid injections for ≥3 months, and absence of planned knee replacement within 6 months); (3) That continuation therapy requires documentation of improvement in pain/functional capacity and ≥6 months elapsed since last injection; (4) That CPT 20610 is covered if selection criteria are met, while CPT 20611, 27369, 73580, 77002, 0232T, 20600, 20604, 20605, 20606 are NOT covered for the indications listed in this policy; (5) That experimental/investigational indications (e.g., viscosupplementation in joints other than knee, combination with stem cells/PRP, patellofemoral arthritis) are not approved for coverage. Contact Aetna to confirm whether this policy remains current or has been superseded.